<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01513070</url>
  </required_header>
  <id_info>
    <org_study_id>SUXIAOJIUXIN2010</org_study_id>
    <nct_id>NCT01513070</nct_id>
  </id_info>
  <brief_title>A Clinical Trials of Quick-Acting Heart Reliever for Moderate Coronary Stenosis</brief_title>
  <official_title>A Randomized Double-blind Placebo-controlled Clinical Trials of the Blood-quickening Stasis-transforming Formula Quick-Acting Heart Reliever for Patients With Moderate Coronary Stenosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guang'anmen Hospital of China Academy of Chinese Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guang'anmen Hospital of China Academy of Chinese Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates the effective power of angina pectoris after Quick-Acting Heart
      Reliever and isosorbide dinitrate interventing respectively the patients with moderate
      coronary stenosis for six months. At the same time, the studying will assess the plaque,
      myocardial blood-supplying,quality of life and observe the end point of the heart (including
      the myocardial revascularization, death and myocardial infarction). The purpose is to study
      the function of the blood-quickening stasis-transforming formula Quick-Acting Heart Reliever
      for moderate coronary stenosis lesions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Blood-quickening stasis-transforming medicinal of Chinese medicinal can ameliorate clinical
      symptoms of coronary artery disease. Quick-Acting Heart Reliever is one of blood-quickening
      stasis-transforming medicinals to relieve angina pectoris in clinic and is especially benefit
      for the patients with moderate coronary stenosis who need not coronary revascularization only
      have medical treatment. But there is no randomized evidence that established the beneficial
      effects of blood-quickening stasis-transforming medicinals to treat moderate coronary
      stenosis lesions. This study is a randomized double-blind placebo-controlled clinical trials.
      A total of 120 consecutive participants with at least one moderate coronary stenosis lesion
      (diameter stenosis 50-75%) will be randomized to two groups: group 1(n =60) will receive
      Quick-Acting Heart and the placebo of isosorbide dinitrate, patients in group 2(n = 60) will
      receive isosorbide dinitrate and the placebo of Quick-Acting Heart for six months. The
      myocardial perfusion imaging and the coronary CT angiography will be used to evaluate the
      effective power of angina pectoris,myocardial blood-supplying，the quality and volume of the
      plaque, diameter stenosis after treating after 6 months and the end point of the heart
      (including death，myocardial infarction and myocardial revascularization which includes
      intracoronary stenting and coronary artery bypass grafting,) after 12 months. The purpose is
      to study the function of Quick-Acting Heart Reliever delaying percutaneous coronary
      intervention(PCI) for moderate coronary stenosis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the effective power of angina pectoris</measure>
    <time_frame>6 months</time_frame>
    <description>the effective power of angina pectoris after Quick-Acting Heart Reliever and isosorbide dinitrate interventing respectively the patients with morderate coronary stenosis for six months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>plaque</measure>
    <time_frame>6 months</time_frame>
    <description>Assess the plaque by the coronary CT angiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>myocardium blood-supply</measure>
    <time_frame>6 months</time_frame>
    <description>Evaluate the myocardium blood-supply by the myocardial perfusion imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the end point of the heart(a composite of cardiovascular events including death, nonfatal myocardial infarction,coronary revascularization, hospitalized unstable angina)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>symptoms score</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MMP-9</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SCD40L</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VEGF</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>bFGF</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Coronary Artery Stenosis</condition>
  <condition>Coronary Heart Disease</condition>
  <arm_group>
    <arm_group_label>Quick-Acting Heart Reliever group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: Quick-Acting Heart Reliever and Placebo of isosorbide dinitrate and Aspirin Enteric-coated Tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Isosorbide Dinitrate group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Isosorbide Dinitrate and Placebo of Quick-Acting Heart Reliever and Aspirin Enteric-coated Tablets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Quick-Acting Heart Reliever</intervention_name>
    <description>Quick-Acting Heart Reliever，200mg，tid，po. for six months</description>
    <arm_group_label>Quick-Acting Heart Reliever group</arm_group_label>
    <other_name>Suxiao Jiuxin Pill</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isosorbide Dinitrate</intervention_name>
    <description>Isosorbide Dinitrate，10mg，tid，po. for six months</description>
    <arm_group_label>Isosorbide Dinitrate group</arm_group_label>
    <other_name>Cedocard，Nitrosorbide， Vascardin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo of Isosorbide Dinitrate</intervention_name>
    <description>Placebo of Isosorbide Dinitrate，10mg，tid，po. for six months</description>
    <arm_group_label>Quick-Acting Heart Reliever group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin Enteric-coated Tablets</intervention_name>
    <description>Aspirin Enteric-coated Tablets，100mg，qd，po. for six months</description>
    <arm_group_label>Quick-Acting Heart Reliever group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo of Quick-Acting Heart Reliever</intervention_name>
    <description>Placebo of Quick-Acting Heart Reliever，200mg，tid，po. for six months</description>
    <arm_group_label>Isosorbide Dinitrate group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin Enteric-coated Tablets</intervention_name>
    <description>Aspirin Enteric-coated Tablets，100mg，qd，po. for six months</description>
    <arm_group_label>Isosorbide Dinitrate group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subjects 30-75 years of age

          -  Angina or CAD patient

          -  Diameter stenosis 50-75% in at least one main coronary artery (Confirmed by coronary
             arteriography or coronary CT angiography)

          -  Not received percutaneous coronary intervention(PCI)

          -  Heart blood stasis obstruction syndrome according to TCM syndrome differentiation

          -  Provide written informed consent.

        Exclusion Criteria:

          -  Heart transplant or history of CABG or history of percutaneous transluminal coronary
             angioplasty (PTCA) with a drug-eluting stent.

          -  Left ventricular ejection fraction &lt; 35%

          -  Acute myocardial infarction within 4 weeks prior to inclusion

          -  The contractive pressure &gt; 160 mmHg or diastolic pressure &gt;100 mmHg

          -  Severe valvular heart disease

          -  Insulin-dependent diabetes mellitus

          -  Serious heart, lung, liver, kidney and brain or other primary complications

          -  Mental patients

          -  Diagnosed or suspected tumor

          -  Allergic persons

          -  Pregnant, breastfeeding, or intends to become pregnant during the course of the study
             (females only)

          -  Patients not willing to or not able to give the informed consent to participate in the
             study

          -  The patients who are attending other clinical trial

          -  The person maybe loss for some reason such as work or life condition according to the
             investigator's judgement
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jie Wang, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Guang'anmen Hospital of China Academy of Chinese Medical Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Guang'anmen Hospital of China Academy of Chinese Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100053</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 16, 2012</study_first_submitted>
  <study_first_submitted_qc>January 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 20, 2012</study_first_posted>
  <last_update_submitted>August 3, 2014</last_update_submitted>
  <last_update_submitted_qc>August 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 5, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Guang'anmen Hospital of China Academy of Chinese Medical Sciences</investigator_affiliation>
    <investigator_full_name>Jie Wang</investigator_full_name>
    <investigator_title>President of Guang'anmen Hospital</investigator_title>
  </responsible_party>
  <keyword>Quick-Acting Heart Reliever</keyword>
  <keyword>Coronary Artery Stenosis</keyword>
  <keyword>Coronary Heart Disease</keyword>
  <keyword>Suxiao Jiuxin Pill</keyword>
  <keyword>Chinese Herbal Drugs</keyword>
  <keyword>Traditional Chinese Medicine</keyword>
  <keyword>Chinese Medicine</keyword>
  <keyword>Angina Pectoris</keyword>
  <keyword>Isosorbide Dinitrate</keyword>
  <keyword>Myocardial Perfusion Imaging</keyword>
  <keyword>Clinical Trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Stenosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Isosorbide</mesh_term>
    <mesh_term>Isosorbide-5-mononitrate</mesh_term>
    <mesh_term>Isosorbide Dinitrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

